KR20220101679A - 뎅기열 질환의 치료 및 예방 - Google Patents

뎅기열 질환의 치료 및 예방 Download PDF

Info

Publication number
KR20220101679A
KR20220101679A KR1020227020173A KR20227020173A KR20220101679A KR 20220101679 A KR20220101679 A KR 20220101679A KR 1020227020173 A KR1020227020173 A KR 1020227020173A KR 20227020173 A KR20227020173 A KR 20227020173A KR 20220101679 A KR20220101679 A KR 20220101679A
Authority
KR
South Korea
Prior art keywords
compound
log
copies
dose
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227020173A
Other languages
English (en)
Korean (ko)
Inventor
올리비아 가브리엘라 엠 괴탈스
바트 루돌프 로마니 케스텔린
바트 헨리 테레시아 스툽스
장-프랑수아 본판티
팀 휴고 마리아 존커스
마닉스 반 루크
수잔 캡틴
요한 네이츠
Original Assignee
얀센 파마슈티칼즈, 인코포레이티드
카톨리에케 유니버시테이트 루벤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티칼즈, 인코포레이티드, 카톨리에케 유니버시테이트 루벤 filed Critical 얀센 파마슈티칼즈, 인코포레이티드
Publication of KR20220101679A publication Critical patent/KR20220101679A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227020173A 2019-11-15 2020-11-13 뎅기열 질환의 치료 및 예방 Ceased KR20220101679A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP19209593 2019-11-15
EP19209593.3 2019-11-15
EP19213851.9 2019-12-05
EP19213851 2019-12-05
EP20171172 2020-04-23
EP20171172.8 2020-04-23
PCT/EP2020/082102 WO2021094563A1 (en) 2019-11-15 2020-11-13 Treatment and prevention of dengue disease

Publications (1)

Publication Number Publication Date
KR20220101679A true KR20220101679A (ko) 2022-07-19

Family

ID=73288639

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227020173A Ceased KR20220101679A (ko) 2019-11-15 2020-11-13 뎅기열 질환의 치료 및 예방

Country Status (14)

Country Link
US (1) US20220409583A1 (https=)
EP (1) EP4058019A1 (https=)
JP (1) JP2023502053A (https=)
KR (1) KR20220101679A (https=)
CN (1) CN114980884A (https=)
AU (1) AU2020382911A1 (https=)
BR (1) BR112022009199A2 (https=)
CA (1) CA3161338A1 (https=)
IL (1) IL292970A (https=)
MX (1) MX2022005879A (https=)
PH (1) PH12022551160A1 (https=)
TW (1) TW202132269A (https=)
UA (1) UA129409C2 (https=)
WO (1) WO2021094563A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023218285A1 (en) * 2022-05-12 2023-11-16 Janssen Pharmaceuticals, Inc. Treatment or prevention of dengue viral infection
WO2025248536A1 (en) * 2024-05-29 2025-12-04 Zydus Lifesciences Limited Novel oxime derivatives to treat viral infections
WO2025253267A1 (en) 2024-06-06 2025-12-11 Janssen Pharmaceuticals, Inc. Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك

Also Published As

Publication number Publication date
UA129409C2 (uk) 2025-04-16
CA3161338A1 (en) 2021-05-20
EP4058019A1 (en) 2022-09-21
JP2023502053A (ja) 2023-01-20
TW202132269A (zh) 2021-09-01
US20220409583A1 (en) 2022-12-29
CN114980884A (zh) 2022-08-30
PH12022551160A1 (en) 2023-09-25
WO2021094563A1 (en) 2021-05-20
MX2022005879A (es) 2022-06-14
AU2020382911A1 (en) 2022-06-30
IL292970A (en) 2022-07-01
BR112022009199A2 (pt) 2022-07-26

Similar Documents

Publication Publication Date Title
Scharton et al. Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment
Perry et al. An iminosugar with potent inhibition of dengue virus infection in vivo
WO2022035911A2 (en) Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent
KR20220101679A (ko) 뎅기열 질환의 치료 및 예방
AU2014318488B2 (en) Deoxynojirimycin derivatives and methods of their using
US10517854B2 (en) Dosing regiments of celgosivir for the treatment of dengue
Watanabe et al. Preclinical antiviral testing for dengue virus infection in mouse models and its association with clinical studies
CA2945825C (en) Inhibition of flaviviruses or chikungunya viruses using retinoic acid analogues
KR102568877B1 (ko) 중증열성혈소판감소증후군 치료 또는 예방용 약학 조성물 및 이의 의약 용도
EP4349335A1 (en) Use of 5-nitro-8-hydroxyquinoline
Snell Examining unmet needs in infectious disease
Lawitz et al. 92 SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY OF VCH-916, A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION
WO2017201030A1 (en) Methods of treating viral infection
CN102335171B (zh) 一类n-(2-噻唑)苯甲酰胺衍生物的应用
EA049504B1 (ru) Лечение и профилактика лихорадки денге
HK40074715A (en) Treatment and prevention of dengue disease
US11000516B2 (en) Dosing regimens of celgosivir for the prevention of dengue
KR102405447B1 (ko) 5-(2-아마노에틸)-디벤조[cd,f]-인돌-4(5H)-온 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 포함하는 항 HIV-1용 약학적 조성물
Thys et al. R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond
EP3960173B1 (en) Enterovirus inhibitor
CN106727574A (zh) 马尼地平在制备治疗黄病毒科病毒感染药物中的应用
WO2014140680A1 (en) Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection
JP2008133190A (ja) プロテアーゼインヒビター
JP2007210987A (ja) ウイルス性疾患の予防または治療剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601